Welcome to our dedicated page for Vtv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on Vtv Therapeutics stock.
vTv Therapeutics Inc. (Nasdaq: VTVT) is a late-stage biopharmaceutical company focused on oral, small molecule drug candidates for diabetes and other chronic diseases. News about VTVT frequently centers on the development of its lead program, cadisegliatin (TTP399), a novel liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment to insulin for people with type 1 diabetes.
Company updates often cover key milestones in the CATT1 Phase 3 trial of cadisegliatin in adults with type 1 diabetes, including trial initiation, randomization of the first study participant, and expectations for topline data. vTv Therapeutics also issues news on its Phase 2 clinical study protocol for cadisegliatin as an adjunctive therapy to insulin in people with type 2 diabetes, developed in collaboration with M42’s Insights Research Organization & Solutions (IROS) for sites in the United Arab Emirates, Jordan, and Tunisia.
Investors following VTVT news can expect regular clinical development updates, such as preclinical and clinical data presentations at scientific meetings, including the INNODIA Symposium at the European Association for the Study of Diabetes Annual Meeting. The company also reports on intellectual property developments, including U.S. patent allowances for crystalline forms of cadisegliatin with patent terms running through 2041.
Another recurring theme in vTv Therapeutics news is financing and corporate activity, such as private placements with healthcare institutional investors and the T1D Fund intended to support the CATT1 Phase 3 trial and broader cadisegliatin program. Updates on participation in investor conferences and changes to scientific advisory structures also appear in the news flow.
For readers tracking VTVT stock, this news page aggregates company press releases and related coverage so they can monitor progress in clinical trials, regulatory interactions, patent protection, and capital-raising efforts tied to vTv Therapeutics’ diabetes-focused pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.